SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice
Justin H. Berger(Children's Hospital of Philadelphia), Daniel P. Kelly(Cardiovascular Institute of the South), Ling‐Ping Lai(National Taiwan University Hospital), Jiten Patel(University of Pennsylvania), Saptarsi M. Haldar(Amgen (United States)), Caitlyn E. Bowman(Williams College), Renee Taing(University of Pennsylvania), Teresa C. Leone(Cardiovascular Institute of the South), Zoltàn Arany(Cardiovascular Institute Hospital), Timothy Matsuura(University of Minnesota System), Jeffrey D. Reagan(Amgen (United States))
Cited by 31
Related Papers
Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis
|Journal of Clinical Investigation|2000|1.3k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|942
A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders
|Proceedings of the National Academy of Sciences|1999|940
The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus
|Journal of Clinical Investigation|2002|879
The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus
|Journal of Clinical Investigation|2002|765